Published in Prostate on October 01, 1999
Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer (2004) 1.73
JunD-mediated repression of GADD45α and γ regulates escape from cell death in prostate cancer. Cell Cycle (2011) 1.63
A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res (2008) 1.56
Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol (2006) 1.48
Paraneoplastic syndromes in prostate cancer. Nat Rev Urol (2010) 1.43
Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol Cell Biol (2001) 1.41
Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer (2011) 1.34
Interleukin-6 regulates androgen synthesis in prostate cancer cells. Clin Cancer Res (2009) 1.32
Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality. Int J Cancer (2009) 1.29
Molecular mechanisms of castration-resistant prostate cancer progression. Future Oncol (2009) 1.26
Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer. Transl Gastrointest Cancer (2012) 1.26
Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer. Br J Cancer (2007) 1.22
The NF-kappaB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches? World J Urol (2007) 1.13
Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol (2010) 1.11
IL-6/IL-6R as a potential key signaling pathway in prostate cancer development. World J Clin Oncol (2011) 1.07
The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumour cells by activating the MAPK pathways. PLoS One (2009) 1.06
Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2. Mol Cancer Ther (2009) 1.02
Phosphorylation of the androgen receptor by PIM1 in hormone refractory prostate cancer. Oncogene (2012) 1.02
Genetic ablation of PKC epsilon inhibits prostate cancer development and metastasis in transgenic mouse model of prostate adenocarcinoma. Cancer Res (2011) 0.98
Osteoblasts induce prostate cancer proliferation and PSA expression through interleukin-6-mediated activation of the androgen receptor. Clin Exp Metastasis (2004) 0.98
Inhibition of STAT3 signaling targets both tumor-initiating and differentiated cell populations in prostate cancer. Oncotarget (2014) 0.97
Loss of let-7 microRNA upregulates IL-6 in bone marrow-derived mesenchymal stem cells triggering a reactive stromal response to prostate cancer. PLoS One (2013) 0.95
Loss of annexin A1 disrupts normal prostate glandular structure by inducing autocrine IL-6 signaling. Carcinogenesis (2009) 0.94
Interleukin-6: a bone marrow stromal cell paracrine signal that induces neuroendocrine differentiation and modulates autophagy in bone metastatic PCa cells. Autophagy (2012) 0.94
Interleukin-6 and oncostatin-M synergize with the PI3K/AKT pathway to promote aggressive prostate malignancy in mouse and human tissues. Mol Cancer Res (2013) 0.94
Autophagy pathway is required for IL-6 induced neuroendocrine differentiation and chemoresistance of prostate cancer LNCaP cells. PLoS One (2014) 0.89
Unveiling the association of STAT3 and HO-1 in prostate cancer: role beyond heme degradation. Neoplasia (2012) 0.89
Necdin, a negative growth regulator, is a novel STAT3 target gene down-regulated in human cancer. PLoS One (2011) 0.89
Consistent interactions between tumor cell IL-6 and macrophage TNF-α enhance the growth of human prostate cancer cells in the bone of nude mouse. Int Immunopharmacol (2011) 0.89
The endogenous cell-fate factor dachshund restrains prostate epithelial cell migration via repression of cytokine secretion via a cxcl signaling module. Cancer Res (2015) 0.87
RhoGDIα suppresses growth and survival of prostate cancer cells. Prostate (2011) 0.86
PI3K/Akt-dependent transcriptional regulation and activation of BMP-2-Smad signaling by NF-kappaB in metastatic prostate cancer cells. Prostate (2009) 0.86
Sodium selenite inhibits interleukin-6-mediated androgen receptor activation in prostate cancer cells via upregulation of c-Jun. Clin Chim Acta (2007) 0.85
Interleukin-1beta-induced promatrilysin expression is mediated by NFkappaB-regulated synthesis of interleukin-6 in the prostate carcinoma cell line, LNCaP. Neoplasia (2002) 0.85
Moringa oleifera pod inhibits inflammatory mediator production by lipopolysaccharide-stimulated RAW 264.7 murine macrophage cell lines. Inflammation (2012) 0.84
Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation. Mol Cancer Ther (2014) 0.84
Differentially Expressed Genes and Signature Pathways of Human Prostate Cancer. PLoS One (2015) 0.82
Vitamin k2, a naturally occurring menaquinone, exerts therapeutic effects on both hormone-dependent and hormone-independent prostate cancer cells. Evid Based Complement Alternat Med (2013) 0.82
Castration-resistant prostate cancer: potential targets and therapies. Biologics (2012) 0.81
The proinflammatory cytokine, IL-6, and its interference with bFGF signaling and PSMA in prostate cancer cells. Inflammation (2013) 0.81
Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells. Br J Cancer (2009) 0.80
Prostate Cancer Stem-like Cells Contribute to the Development of Castration-Resistant Prostate Cancer. Cancers (Basel) (2015) 0.79
IL6 sensitizes prostate cancer to the antiproliferative effect of IFNα2 through IRF9. Endocr Relat Cancer (2013) 0.79
A Paracrine Role for IL6 in Prostate Cancer Patients: Lack of Production by Primary or Metastatic Tumor Cells. Cancer Immunol Res (2015) 0.78
REST reduction is essential for hypoxia-induced neuroendocrine differentiation of prostate cancer cells by activating autophagy signaling. Oncotarget (2016) 0.78
Epidemiological study of prostate cancer (EPICAP): a population-based case-control study in France. BMC Cancer (2014) 0.77
RAMP1 is a direct NKX3.1 target gene up-regulated in prostate cancer that promotes tumorigenesis. Am J Pathol (2013) 0.77
Lenalidomide and cyclophosphamide immunoregulation in patients with metastatic, castration-resistant prostate cancer. Clin Exp Metastasis (2015) 0.75
IL-6 Inhibits the Targeted Modulation of PDCD4 by miR-21 in Prostate Cancer. PLoS One (2015) 0.75
Bacterial Prostatitis Enhances 2-Amino-1-Methyl-6-Phenylimidazo[4,5-b]Pyridine (PhIP)-Induced Cancer at Multiple Sites. Cancer Prev Res (Phila) (2015) 0.75
Granulocyte macrophage colony-stimulating factor may modulate the post-transcription pathway of interleukin-6 expression in prostate carcinoma cells. J Korean Med Sci (2008) 0.75
Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet. Target Oncol (2017) 0.75
Synthesis and in vitro characterization of ionone-based compounds as dual inhibitors of the androgen receptor and NF-κB. Invest New Drugs (2013) 0.75
The sequence of the human genome. Science (2001) 101.55
Genomic sequence sampling: a strategy for high resolution sequence-based physical mapping of complex genomes. Nat Genet (1994) 14.90
'Green revolution' genes encode mutant gibberellin response modulators. Nature (1999) 8.87
The Arabidopsis GAI gene defines a signaling pathway that negatively regulates gibberellin responses. Genes Dev (1997) 7.30
LNCaP model of human prostatic carcinoma. Cancer Res (1983) 7.23
Infection in total knee replacement: a retrospective review of 6489 total knee replacements. Clin Orthop Relat Res (2001) 4.15
Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer (1980) 3.37
Purification of a human prostate specific antigen. Invest Urol (1979) 3.11
Factors responsible for the high perforation rate seen in early childhood appendicitis. Am Surg (1989) 2.92
Carcinoembryonic antigen in patients with different cancers. JAMA (1972) 2.56
Defining and updating the American Cancer Society guidelines for the cancer-related checkup: prostate and endometrial cancers. CA Cancer J Clin (1993) 2.43
A novel Sec18p/NSF-dependent complex required for Golgi-to-endosome transport in yeast. Mol Biol Cell (1997) 2.24
Core outcomes measures for inguinal hernia repair. J Am Coll Surg (1997) 2.17
Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer (1998) 2.15
Characterization of rectal, proximal and distal colon cancers based on clinicopathological, molecular and protein profiles. Int J Oncol (2010) 2.10
Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology (1998) 2.04
Elevated high-sensitivity C-reactive protein levels are associated with local inflammatory findings in patients with osteoarthritis. Osteoarthritis Cartilage (2006) 2.03
American Joint Committee on Cancer prognostic factors consensus conference. Cancer (1999) 2.02
Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res (1988) 1.91
Sec2 protein contains a coiled-coil domain essential for vesicular transport and a dispensable carboxy terminal domain. J Cell Biol (1990) 1.86
Measurement of erythrocyte membrane elasticity by flicker eigenmode decomposition. Biophys J (1995) 1.80
Meta-analysis of thromboembolic prophylaxis after total knee arthroplasty. J Bone Joint Surg Br (2000) 1.77
SV40 neutralizing antibodies in sera of US residents without history of polio immunization. Nature (1971) 1.77
Race-related differences in breast cancer patients. Results of the 1982 national survey of breast cancer by the American College of Surgeons. Cancer (1985) 1.76
Prostatic-specific antigen: an immunohistologic marker for prostatic neoplasms. Cancer (1981) 1.73
Complications and recommended practices for electrosurgery in laparoscopy. Am J Surg (2000) 1.68
Human immunodeficiency virus infections in teenagers. Seroprevalence among applicants for US military service. The Walter Reed Retrovirus Research Group. JAMA (1990) 1.67
Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer (1998) 1.61
Validity of register data on acute myocardial infarction and acute stroke: the Skaraborg Hypertension Project. Scand J Soc Med (1993) 1.59
Secondary carcinomas of the kidney. J Urol (1975) 1.59
The National Cancer Data base Report on increased use of brachytherapy for the treatment of patients with prostate carcinoma in the U.S. Cancer (1999) 1.58
The chondroitin sulfate form of invariant chain can enhance stimulation of T cell responses through interaction with CD44. Cell (1993) 1.58
Clinical highlights from the National Cancer Data Base: 1994. CA Cancer J Clin (1994) 1.58
Return to work after inguinal hernia repair. Surgery (2001) 1.55
Spinous process osteotomies to facilitate lumbar decompressive surgery. Spine (Phila Pa 1976) (1999) 1.55
The 1982 national survey of carcinoma of the breast in the United States by the American College of Surgeons. Surg Gynecol Obstet (1984) 1.54
Self-inflicted gunshot wounds: lethality of method versus intent. Am J Psychiatry (1985) 1.50
Two mechanisms for growth inhibition by elevated transport of sugar phosphates in Escherichia coli. J Gen Microbiol (1992) 1.48
The National Cancer Data Base report on race, age, and region variations in prostate cancer treatment. Cancer (1997) 1.47
Cost-effective prostate cancer detection. Reduction of low-yield biopsies. Investigators of the American Cancer Society National Prostate Cancer Detection Project. Cancer (1994) 1.46
The mortality of Appalachian coal miners, 1963 to 1971. Arch Environ Health (1974) 1.45
Combined spinal-epidural anesthesia for outpatient surgery. Dose-response characteristics of intrathecal isobaric lidocaine using a 27-gauge Whitacre spinal needle. Anesthesiology (1995) 1.41
The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men. Cancer (1991) 1.39
Tumor grade and stage as prognostic variables in upper tract urothelial tumors. Cancer (1988) 1.35
CEA as a monitor of gastrointestinal malignancy. Cancer (1975) 1.33
Selective activation of the fatty acid synthesis pathway in human prostate cancer. Int J Cancer (2000) 1.33
Localization of Chlamydia trachomatis infection by direct immunofluorescence and culture in pelvic inflammatory disease. Am J Obstet Gynecol (1986) 1.33
Acupuncture for chronic low back pain in older patients: a randomized, controlled trial. Rheumatology (Oxford) (2003) 1.32
Modern prostate brachytherapy. CA Cancer J Clin (2001) 1.31
CXCR-4, a chemokine receptor, is overexpressed in and required for proliferation of glioblastoma tumor cells. J Surg Oncol (1998) 1.29
Trends in patterns of care for prostatic cancer, 1974-1983: results of surveys by the American College of Surgeons. J Urol (1986) 1.29
Noninvasive breast carcinoma: results of a national survey by the American College of Surgeons. Ann Surg (1980) 1.27
Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer (1993) 1.27
The results of a five-year early prostate cancer detection intervention. Investigators of the American Cancer Society National Prostate Cancer Detection Project. Cancer (1996) 1.25
Improvement of in-rumen digestibility of alfalfa forage by genetic manipulation of lignin O-methyltransferases. Transgenic Res (2001) 1.24
The association of benign prostatic hyperplasia and cancer of the prostate. Cancer (1992) 1.22
Evidence for non-selective preservation of organic matter in sinking marine particles. Nature (2001) 1.20
Population-based cohort study of microbial keratitis in Scotland: incidence and features. Cont Lens Anterior Eye (1999) 1.19
Translational control of the antiapoptotic function of Ras. J Biol Chem (2000) 1.19
Prostate antigen: a new potential marker for prostatic cancer. Prostate (1981) 1.18
Analysis of glycosylation of prostate-specific membrane antigen derived from LNCaP cells, prostatic carcinoma tumors, and serum from prostate cancer patients. Prostate Suppl (1996) 1.17
The National Cancer Data Base report on bladder carcinoma. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer (1996) 1.13
Correlations of the orthogonal electrocardiogram and vectorcardiogram with consitutional variables in 518 normal men. Circulation (1967) 1.12
Enhanced learning of proportional math through music training and spatial-temporal training. Neurol Res (1999) 1.11
Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate (1999) 1.11
Use of human prostate-specific antigen in monitoring prostate cancer. Cancer Res (1981) 1.10
Acanthamoeba keratitis in Scotland: risk factors for contact lens wearers. Cont Lens Anterior Eye (1999) 1.09
Estimated blood loss and transfusion requirements of radical cystectomy. J Urol (2001) 1.09
A murine renal cell carcinoma. J Natl Cancer Inst (1973) 1.09
Why is the prostate cancer death rate declining in the United States? Cancer (1998) 1.09
Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate (1998) 1.09
A prostate antigen in sera of prostatic cancer patients. Cancer Res (1980) 1.08
Matrix metalloproteinase homologues from Arabidopsis thaliana. Expression and activity. J Biol Chem (1999) 1.07
Management and survival of carcinoma of the colon: results of a national survey by the American College of Surgeons. Ann Surg (1978) 1.07
Reduced penetrance alleles for Huntington's disease: a multi-centre direct observational study. J Med Genet (2007) 1.07
Sensitivity of magnetic resonance imaging in the detection of colorectal liver metastases. Ann R Coll Surg Engl (2008) 1.07
Mesenchymal cells isolated after acute lung injury manifest an enhanced proliferative phenotype. J Clin Invest (1992) 1.06
Placental pathology in systemic lupus erythematosus: a prospective study. Am J Obstet Gynecol (1998) 1.06
Inhibition of Myc-dependent apoptosis by eukaryotic translation initiation factor 4E requires cyclin D1. Oncogene (2000) 1.06
Surgical correction of primary hyperparathyroidism improves quality of life. Surgery (1998) 1.06
Inhibition of natural killer cell activation signals by killer cell immunoglobulin-like receptors (CD158). Immunol Rev (2001) 1.06
Components of variance for vibratory and thermal threshold testing in normal and diabetic subjects. J Diabetes Complications (1995) 1.06
Prostate cancer: progress and change. CA Cancer J Clin (1978) 1.06
The histology of liver tumors in oral contraceptive users observed during a national survey by the American College of Surgeons Commission on Cancer. Cancer (1979) 1.05
A comparison of breast, colorectal, lung, and prostate cancers reported to the National Cancer Data Base and the Surveillance, Epidemiology, and End Results Program. Cancer (1997) 1.05
Trends in prostate cancer care in the United States, 1974-1990: observations from the patient care evaluation studies of the American College of Surgeons Commission on Cancer. CA Cancer J Clin (1993) 1.05
Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate (1997) 1.05
Pathogenesis of pulmonary fibrosis: platelet-derived growth factor precedes structural alterations in the Hermansky-Pudlak syndrome. J Lab Clin Med (1994) 1.04
Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res (1980) 1.04
Prostate-specific membrane antigen: current and future utility. Semin Urol Oncol (1998) 1.04
The National Cancer Data Base report on longitudinal observations on prostate cancer. Cancer (1996) 1.04
Prostate-specific antigen levels in young white and black men 20 to 45 years old. Urology (2000) 1.04
The national survey of prostate cancer in the United States by the American College of Surgeons. J Urol (1982) 1.04
American Cancer Society guideline for the early detection of prostate cancer: update 1997. CA Cancer J Clin (1997) 1.04